Vascular endothelial growth factor receptor 2 (VEGFR-2) is known as one of the important antigens playing a vital role in angiogenesis. In this study, phage display technology (PDT) was used to produce a single-chain variable fragment (scFv) antibody against a region of the domain 3 in VEGFR-2 called kinase insert domain receptor 3 (KDR3).
INTRODUCTION
Angiogenesis refers to the formation of new blood vessels from pre-existing ones. This phenomenon is Corresponding Author: Jalal Abdolalizadeh, PhD; Clinical Biochemistry, Drug Applied Research Center, Tabriz a naturally occurring multi-stage process although can be seen in pathophysiological conditions. Angiogenesis is also a procedure required for invasion, metastasis, and cancer progression. In this respect, the vascular, Ser264, Ser265, and Lys266. 13 endothelial growth factor (VEGF) is known as a key factor in the proliferation and migration of endothelial cells, which is the basis of new vein formation. 1, 2 The biological action of this VEGF is applied to target cells by interacting with tyrosine kinase receptors on the cell plasma membrane. These receptors, after binding to their ligand, become dimers and are auto phosphorylated, eventually inducing an intracellular cascade of events. Known tyrosine kinase receptors associated with these growth factors are VEGFR-1, VEGFR-2, VEGFR-3, and Neuropilins. 3, 4 The VEGFA is a major factor in angiogenesis and acts through activating VEGFR-1 and VEGFR-2 receptors. 5 There is also a consensus that the VEGF and its most important receptor, the VEGFR-2, are the main regulators of angiogenesis. 6 VEGF signaling and its intracellular cascade results to angiogenesis in the tumor similarly stimulates rapid growth of the tumor and facilitates metastasis. 7 Therefore, preventing this cascade can result in anti-angiogenic and anti-tumor response. 8 Several monoclonal antibodies have been further produced against the VEGF or the VEGFR, which prevent or significantly reduce angiogenesis. Human antibodies are more preferred than murine and chimeric antibodies because they induce low immunogenicity in their hosts. One of the methods for producing fully human antibodies is the phage display technology (PDT), which was first introduced by Smith in 1985. 9 The PDT can be used to produce phage libraries expressing a single-chain variable fragment (scFv) antibody. These libraries with their high diversity can help in the production of high-affinity antibodies against almost all antigens. The scFv antibody against the KDR3 can be also produced using the PDT. The scFv antibody fragments are classified as the fourth generation of antibodies and they are fully humanized, so they have been used in clinic without the immunogenicity concerns. In pharmacokinetic insight, the blood clearance of scFv as an important issue, is favorable. Due to the elimination of Fc receptor in this kind of antibody, utilization of scFv results in low nonspecific binding to the Fc receptors that expressed on the normal cells. 10 The scFv fragments show high penetration in tumor cells and tissues which is related to their small size and low molecular weight. Easiness in large scale production of scFv and no need to animals for this process introduce scFv as a strong agent for clinical and laboratory applications.
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The extracellular fragment of kinase insert domain receptor 3 (KDR3) is composed of seven immunoglobulin-like domains. There is also a tyrosine kinase domain located in the intracellular side. Among the seven extracellular domains with 1356 amino acids, it has been shown that domains 1-3, especially domain 3, are sufficient and necessary for high affinity binding with VEGF. [12] [13] [14] It has been also shown that the domain 3 has two different sets of amino acids playing a vital role in antibody binding to the receptor, one of Ile256, Asp257, Glu261, Leu313, and Thr315, and another of Tyr262, Pro263
The purpose of this study was to isolate mAb against a peptide, designed from a fragment of KDR3 using PDT.
MATERIALS AND METHODS

Designing of KDR3 Peptide for Selection Phase
Various characteristics of the KDR3 peptide were studied as antigens including epitope, antigenicity, and especially the accessibility domains, using the online database of IEDB Analysis Resource 15 to identify regions of this target protein that can be employed to prepare antibodies via PDT. The Ethics Committee of Tabriz University of Medical Sciences approved the research project (N. 94.2-1.8).
Selection of scFv by Biopanning
After dissolving the KDR3 peptide in a carbonate buffer at pH 8.5, 100 µL was added to the wells of 96-well plates and incubated overnight at 4°C. The biopanning procedure for antibody selection was performed as previously described. 16, 17 Polyclonal and monoclonal phage ELISA were also used to verify the ability of scFv expression.
Homology Modeling, Assessment and Docking
Using automodel.very_fast method in Modeller v9.18, Modeller was performed to get an approximate model very quickly. Four scFv sequences (A9K, F12K, G12K, and H6K) were also used as input in automodel.very_fast method. Initially, BlastP was performed against the given sequences and three templates were found for each sequence. Then a multiple sequence alignment was produced using Clustal Omega. Automodel.very_fast method in Modeller created a model for each sequence. To end with, ClusPro docking server 18 was used for binding affinity calculation of each predicted model with KDR3. The best models were used in Modeller v9.18 software for performing HM via the crystal structures of 5GRW-A, 5gs1-C, and 5GS3-H as the templates. Modeller v9.18 software was also applied for performing HM using the crystal structures of 5GRW-A, 5gs1-C and 5GS3-H as the templates. As mentioned above, BlastP was performed against the given sequence and three templates were found, which had been used as inputs for multiple sequence alignment via Clustal Omega. For further analyses, among 10000 generated models, 10 top models were chosen based on their molecular pdf (molpdf) score, GA341 score, DOPE score, normalized dope score, as well as DOPEHR score. The refinement and energy minimizing of the selected model was further carried out using GalaxyRefine 19 and NOMAD-REF 20 servers. VADAR (Volume, Area, Dihedral Angle Reporter) server 21 and ProSA 22 were also applied for evaluation of the quality of the homology model and assessment of the accuracy and reliability of the modelled structures. TM-align web tool 23 was then performed to compare the resulted 3D model of A9K with the best template structure (Chain H from PDB ID: 5GS3). A9K-KDR3 (PDB:3V2R chain R) binding affinity and docking score were similarly assessed using both ClusPro docking and HADDOCK servers.
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Expression and Extraction of scFv in the Bacterial Expression System
In order to express the selective scFv (A9K), the phage derived from colony A9K was added to host E. coli (HB2151 strain). The expression and extraction of scFv were also performed as previously described. 16, 17 Purification of scFv by Affinity Chromatography using Protein A Sepharose 4B
Anti-KDR3 scFv antibody fragments were purified by affinity chromatography using protein A Sepharose 4B. 25 Briefly, 5 mL of protein A-Sepharose 4B column (Amersham Biosciences, Freiburg, Germany) was packed and then equilibrated with the binding buffer (1x PBS, pH 7.4). The mixture of the secreted scFv and periplasmic fractions were then applied to the column at a flow rate of 50 cm/h. Afterwards; the column was washed via washing buffer with five column volumes and finally scFvs were eluted with elution buffer (0.1M Glycine-HCl, pH 2.7) under isocratic conditions. The fractions containing antibody fragments were pooled and the pH was adjusted to 7.5 by 2 M Tris-HCl, pH 8.0. Fractions were also assessed by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the pure fractions were collected. The samples were dialyzed overnight against 1x PBS and the final products were quantified using a UV spectrophotometer at optical density (OD) of 280 nm.
SDS-PAGE and Western Blot Analysis
To evaluate the size and purity of the scFv fragments, the products were electrophoresed on a 12% SDS-PAGE. The bands were then visualized after Coomassie Blue-R250 staining.
The western blot was also designed to confirm the function of purified scFv. For this purpose, after electrophoresis, the products were transferred to a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA, USA) using a semidry transfer device (Amersham Biosciences, Freiburg, Germany). After blocking the PVDF membrane with 5% skim milk, the primary antibody of mouse anti-myc antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added with the ratio of 1 to 1000. After washing with TBST, the secondary antibody of the HRP-conjugated antimouse IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was applied with the ratio of 1 to 2500. Then, the membrane was rewashed and the enhanced chemiluminescence (ECL) substrate (Amersham Biosciences, Freiburg, Germany) was added immediately to observe the bands.
Dot Blotting Analysis
To test the specificity and cross-reactivity of the obtained scFvs, a dot blotting test was employed. Bovine serum albumin (BSA) and KDR3 peptide were blotted onto PVDF. Then, the membrane was blocked and incubated with scFv. After washing, the membrane was incubated with mouse anti-myc antibody and subsequently with HRP-conjugated anti-mouse IgG. The ECL substrate was also used for the visualization of protein bands.
Evaluating the Binding Affinity of scFv
The SPR method with a multi-parameter SPR device (MP-SPR Navi 210A, BioNavis Ltd, Finland) was used to study the purified scFv kinetic properties and to evaluate its binding affinity to the extracellular KDR3 protein (KDR3 peptide).
First, gold chip was placed at RT in the presence of 5mM MUA (11-mercaptoundecanoic acid) in ethanol and Milli-Q-water, respectively, at a ratio of 7 to 3. After 24 hours, the chip was washed several times with PBS buffer and ethanol. 27 The MUA-sensor was then placed in the SPR instrument. The device started to work by passing the PBS buffer. Next, the sensor surface was washed with NaCl (2 M) and NaOH (0.1 M). To activate the chip surface, the EDC (0.2 M) and NHS (0.05 M) solutions were injected at a ratio of 1 to 1. Immediately after activation, the scFv solution was injected in the PBS buffer with a flow rate of 10μl/min for 8 min on a part of the slide surface. The other part of the slide without scFv was introduced as a negative control to the device. The ethanolamine-HCl (1.0 M) blocker solution; and then, serial concentrations of KDR3 peptide were added to the chip in the PBS buffer. Finally, the kinetic properties of affinity and dissociation were analyzed using the SPR NaviTM Data Viewer software.
IF Microscopy
Human Umbilical Vein Endothelial Cells (HUVEC) were cultured in RPMI 1640 medium (Flow Laboratories, Opera, Italy) containing 10% FBS. The plate was incubated with confluence about 70% overnight with 5% CO 2 at 37°C. After washing, the plate was blocked by blocker solution which was followed by addition of 10 μg/mL of the produced scFv to the cells. After washing the cells, FITC-labeled goat anti-mouse IgG was added and incubated for 1 hour in RT. After final washing and adding 90% glycerol, the cells were examined under a fluorescence microscope.
RESULTS
Peptide Design from KDR3
Beside the IEDB online database, further investigation into the biochemical structure of the KDR3 protein by the VMD 1.9.2 software determined that the 15-aa peptide with the sequence of -COOH PSSHHQHKKLVNRDL NH2-could be used.
This fragment synthesized by Mimotopes Co. (Australia) chemically with 95% purification, was called KDR3 peptide. The peptide was also evaluated and verified by mass spectrophotometry and HPLC. The availability of the fragment selected as the target, which was obtained by the IEDB Analysis Resource was shown in Figure 1 .
According to the scores of this database, the amino acids which were above the threshold line on the graph were fully available on the protein surface. Other features including Epitope and Antigenicity could be reviewed by this database. 
Modeling, Assessment, and Docking
The best results were selected for all docked models based on the lowest calculated energy (E=0.50E rep +−0.20E att +600E elec +0.25E DARS ); which were -337.0, -294.5, -315.6 and -333.7 for A9K, F12K, G12K, and H6K, respectively. Quality assessment of the best model was also checked using VADAR (Figure 2 ). Compared with experimentally-validated protein structures (Figure 2A ), the total model quality calculated by ProSA Z-score was -7.66 implicating a very high quality of the model. ProSA web tool ( Figure  2B ) confirmed the local model quality. Accuracy of HM prediction method assessed based on TM-score of A9K-5GS3-H structural alignment was equal to 0.83 (Figure 3 ).
Evaluating the Expression of Antibody Fragments
The phage obtained from the A9K clone, which was found to be a proper clone for continued testing after sequencing and docking, was transferred to the HB2151 strain of host E. coli. After its induction by Isopropyl-beta-D-thiogalactopyranoside (IPTG), scFvs were also extracted from the periplasmic and cytoplasmic regions and electrophoresed by 12% SDS-PAGE. The protein bands were observed using the Coomassie Brilliant Blue staining.
The extracted scFvs shown in Figure 4 were within the expected weight range (approximately 28 kDa) and the expressions were obvious at different times of induction.
Western Blotting and Dot Blotting of Purified scFv
A9K scFv was resolved by 12% SDS-PAGE under reducing conditions. Then, western blotting analysis was done using anti-Myc and HRP conjugated antimouse antibodies. ECL substrate was used for the visualization of protein bands. As a result, Figure 5A and Figure 5B represented SDS-PAGE and western blot analysis of purified scFv with a 28 kDa molecular weight. By the ImageJ software, antibody purification was estimated to be about 95%. Dot blotting analysis showed specific binding of purified scFv to KDR3 peptide with no cross-reactivity with BSA ( Figure 5C ). Investigation into Kinetic Properties of scFv Using SPR Figure 6 showed the dose-response sensograms of the reaction between the scFv stabilized on the chip surface and different concentrations of peptide from 0.25 to 5 μM. The results of affinity (Ka) and dissociation (Kd) of different concentrations of KDR3 peptide were also analyzed by the software and the affinity constant (KD) was calculated based on these results. These data indicated that Ka was 6. 
IF Analyses
To evaluate the cellular function of scFv A9K, it's binding to HUVECs, cultured and fixed in the plate, were examined using a fluorescence microscope. The selected specific scFvs binding with the cells were shown in Figure 7 . 
DISCUSSION
Monoclonal antibodies can detect and inhibit cancer cells through binding to specific antigens on the cell surface. 28 The success of this method depends, to a large extent, on finding an ideal antigen for cancer cell targeting. In this respect, the KDR3 is known as one of the key antigens on the cancer cell surface, playing a role in the angiogenesis. Therefore, the prevention of angiogenesis by linking the scFv to the KDR3 can prevent cancer growth or metastasis. This does not happen sometimes because angiogenesis is regulated by multiple pathways and by blocking a path (VEGFR-2 / VEGF), other pathways may be activated and angiogenesis occurs. 6 In one of these ways, the produced scFv can be linked to the core shell of the nanoparticles carrying therapeutic drugs and to overcome this problem, it is released to be specifically linked to KDR3. This function not only reduces the process of angiogenesis, but also leads to the release of nanoparticle contents on cancer cells and destroys them. Today, there is a growing trend in targeted therapy with nanoparticles. 29, 30 Several studies have also shown that the most important fragments of KDR3 for antibody production are the first to the third domains, especially the third domain. 12, 13 In the light of previous studies, a segment of the KDR3 was also selected with regard to its accessibility and design for peptide synthesis. Biopanning steps were also repeated four times, usually three to four steps. The expression level of the selected scFv in the bacterial expression vector had a proper effect. This level of expression might be due to the use of an appropriate phagemid vector, which could be found in this type of library. These manipulated phagemid vectors were capable of penetrating the bacteria, for easy cloning and rapid proliferation. 16, 31 The scFvs could be extracted from both the periplasmic and cytoplasmic spaces using the correct extraction method. In the periplasmic space, the protein could have the correct folding and high sustainability. 32 In this study, the production of scFv was optimized. There are many factors involved in protein production, 33 namely time, IPTG level, ampicillin, temperature, and bacterial growth OD in the present study. In the literatures, the induction by IPTG were considered at in the middle of the growth phase i.e. OD 0.6 but it could be done at the end of the growth phase and even the stationary phase i.e. ODs higher than 0.6. 33, 34 The results of this study showed that the highest scFv expression was related to the time, about 11 hours after induction with IPTG in OD of 1.7. Moreover, the best values for other items included IPTG of 0.2mM, temperature of 28°C and 50 μg/mL of ampicillin to achieve maximum scFv expression. In other studies, reported that used 0.2-1 mM IPTG and 25-30°C temperature. [31] [32] [33] [34] [35] [36] Affinity chromatography with a stabilized biomolecule, such as protein A, had a high potential for absorbing antibodies. It was found that the efficiency of this purification method was high, but it was uneconomical due to the costly nature of these columns at the industrial scale.
Analyzing the purity of antibodies by observing the bonds formed in SDS-PAGE revealed purification with a high yield of about 90%. The yield of antibody in this one-step purification method was more significant than the yield in other purification methods. 37 The western blot method was also used to verify the expression. The western blotting and dot blotting techniques confirmed the purified scFv function. Biosensor tests, including SPR, are capable of accurately measuring the signals from ligand-receptor or antigen-antibody binding, and recording their activity at the molecular level. These experiments are quite quantitative and feasible for samples with a low amount and in the least time with high sensitivity. By analyzing the purified scFv binding affinity when comparing them with other antibodies, it was found that the given antibody had acceptable binding affinity. In the studies that scFv fragments have been used to the cell surface receptors as targets, the binding affinity were in line with the results of this study. Whereas, binding affinity in the studies that used scFv to target VEGFR-2 were in the range of nano and picomolar in unit. However, the high binding affinity of an antibody is not responsible for its better efficacy. 38 The results of fluorescence microscopy demonstrated that the isolated scFv was linked to the KDR3 cell surface, indicating the proper functioning of the scFv. The fluorescence signal in these cells was slightly lower than what was expected, probably because when the scFv was bound to the receptor (KDR3) on the living cell surface, a large number of them could enter into the cell by endocytosis. In the final stages, when the conjugated antibody was added, the amount of scFv linked to the KDR3 will could decrease on the cell surface, thereby reducing the fluorescence signal. To address this problem, the cells were required to be fixed from the beginning, or the primary FITC scFv was needed to be used in a single step.
We isolated and purified an anti-human KDR3 scFv fragment by using of PDT. Since the functionality of the isolated scFv was confirmed using three criteria i.e. in silico docking, SPR and IF, it would be used to detect KDR3 as an effective target in the human cancers. However, to use this scFv in cancer immunotherapy, we shall focus on affinity maturation and in vivo models using computational design/protein engineering and animal models.
In this study, a novel scFv capable of binding KDR3 was isolated and purified, and its function was investigated and verified on the cell surface.
At present, it is possible to label the scFv with radioactive or fluorescence materials for application in detection methods, both in vitro and in vivo. In general, it is hoped to enhance the effectiveness of antibodies in future investigations in all settings used for therapeutic, diagnostic and imaging purposes.
